No Data
No Data
Jaguar Health to Present Initial Results From the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome With Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Trending Stocks Today | Baijiayun Soars 74.33%
12 Health Care Stocks Moving In Thursday's Intraday Session
Jaguar Health's Napo Reports Preliminary Results From IIT Trial of Crofelemer
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to Be Presented at April 2025 ELITE PED-GI Congress
Jaguar Health Files to Sell 1.29M Shares of Common Stock for Holders